![Transparency Market Researchが調査・発行した産業分析レポートです。乳がん診断の世界市場2019-2027：技術別（画像、組織生検検査、分子検査）、がん種類別、エンドユーザー別 / Breast Cancer Diagnostics Market (Technique: Imaging, Tissue Biopsy Tests, and Molecular Testing; Cancer Type: Ductal Carcinoma In Situ [DCIS] and Invasive Breast Cancer; and End User: Hospitals & Ambulatory Surgery Centers, Diagnostic Laboratories, and Research & Academic Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027 / TMR2006030資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/99x123xreport-contents-91.gif.pagespeed.ic.cYgo-ZH9PJ.jpg) | • レポートコード：TMR2006030 • 出版社/出版日：Transparency Market Research / 2020年3月 • レポート形態：英文、PDF、207ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、乳がん診断の世界市場について、序論、仮定・調査手法、エグゼクティブサマリー、市場動向、キーインサイト、技術別（画像、組織生検検査、分子検査）分析、がん種類別分析、エンドユーザー別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東アフリカ）分析、競争状況などを総合的に調査・分析して掲載しております。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場動向 ・キーインサイト ・乳がん診断の世界市場規模：技術別（画像、組織生検検査、分子検査） ・乳がん診断の世界市場規模：がん種類別 ・乳がん診断の世界市場規模：エンドユーザー別 ・乳がん診断の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東アフリカ） ・競争状況 |
Breast Cancer Diagnostics Market – Scope of the Report
TMR’s report on the global breast cancer diagnostics market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2019 to 2027. The report provides the revenue of the global breast cancer diagnostics market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global breast cancer diagnostics market for the forecast period.
The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global breast cancer diagnostics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of top-down and bottom-up approaches to study various phenomena in the global breast cancer diagnostics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the global breast cancer diagnostics market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global breast cancer diagnostics market. The next section of the global breast cancer diagnostics market report highlights the USPs, which include technological advancements and breast cancer epidemiology.
The report also delves into the competitive landscape of the global breast cancer diagnostics market. Key players operating in the global breast cancer diagnostics treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global breast cancer diagnostics treatment market report.
Key Questions Answered in Global Breast Cancer Diagnostics Market Report
What is the sales/revenue generated by different breast cancer diagnostics across all the regions during the forecast period?
What are the major drivers, restraints, and opportunities in the global market?
Which region is set to expand at the fastest CAGR during the forecast period?
Which segment will have the highest revenue globally in 2027 and which product will expand at the fastest CAGR during the forecast period?
Breast Cancer Diagnostics Market – Research Objectives and Approach
The comprehensive report on the global breast cancer diagnostics market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the global breast cancer diagnostics market. It is followed by market introduction, market dynamics, and an overview of the global breast cancer diagnostics market, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the breast cancer diagnostics market. The next section of the global breast cancer diagnostics market report highlights the USPs, including technological advancements and breast cancer epidemiology in the global breast cancer diagnostics market.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
Revenue generated by key breast cancer diagnostics manufacturers has been mapped to ascertain the size of the global breast cancer diagnostics market in terms of value. The forecast presented here assesses the total revenue generated by breast cancer diagnostics. In order to provide an accurate forecast, we took into consideration the parent cancer diagnostics market.
The report analyzes the global breast cancer diagnostics market in terms of technique, cancer type, end user, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the breast cancer diagnostics market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Breast Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Breast Cancer Diagnostics Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Breast Cancer Diagnostics Market Analysis and Forecast, 2018–2028
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Breast Cancer Epidemiology, by Key Countries/Region
5.3. Breast Cancer Epidemiology
6. Global Breast Cancer Diagnostics Market Analysis and Forecast, by Technique
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Technique, 2018–2028
6.3.1. Imaging
6.3.1.1. Mammography
6.3.1.1.1. Analog Mammography
6.3.1.1.2. Digital Mammography
6.3.1.1.3. Breast Ultrasound System
6.3.1.1.4. MRI Scan
6.3.1.1.5. PET/CT Scan
6.3.2. Tissue Biopsy Tests
6.3.3. Molecular Testing
6.4. Market Attractiveness Analysis, by Technique
7. Global Breast Cancer Diagnostics Market Analysis and Forecast, by Cancer Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Cancer Type, 2018–2028
7.3.1. Ductal Carcinoma In Situ (DCIS)
7.3.2. Invasive Breast Cancer
7.3.2.1. Invasive Ductal Carcinoma
7.3.2.2. Invasive Lobular Carcinoma
7.3.2.3. Metastatic Breast Cancer
7.3.2.4. Others
7.4. Market Attractiveness Analysis, by Cancer Type
8. Global Breast Cancer Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2018–2028
8.3.1. Hospitals & Ambulatory Surgery Center
8.3.2. Diagnostic Laboratories
8.3.3. Research & Academic Institutes
8.4. Market Attractiveness Analysis, by End-user
9. Global Breast Cancer Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Global Breast Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Technique, 2018–2028
10.3.1. Imaging
10.3.1.1. Mammography
10.3.1.1.1. Analog Mammography
10.3.1.1.2. Digital Mammography
10.3.1.2. PET/CT Scan
10.3.2. Tissue Biopsy Tests
10.3.3. Molecular Testing
10.4. Market Value Forecast, by Cancer Type, 2018–2028
10.4.1. Ductal Carcinoma In Situ (DCIS)
10.4.2. Invasive Breast Cancer
10.4.2.1. Invasive Ductal Carcinoma
10.4.2.2. Invasive Lobular Carcinoma
10.4.2.3. Metastatic Breast Cancer
10.4.2.4. Others
10.5. Market Value Forecast, by End-user, 2018–2028
10.5.1. Hospitals & Ambulatory Surgery Center
10.5.2. Diagnostic Laboratories
10.5.3. Research & Academic Institutes
10.6. Market Value Forecast, by Country, 2018–2028
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Technique
10.7.2. By Cancer Type
10.7.3. By End-user
10.7.4. By Country
11. Europe Global Breast Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Technique, 2018–2028
11.3.1. Imaging
11.3.1.1. Mammography
11.3.1.1.1. Analog Mammography
11.3.1.1.2. Digital Mammography
11.3.1.2. PET/CT Scan
11.3.2. Tissue Biopsy Tests
11.3.3. Molecular Testing
11.4. Market Value Forecast, by Cancer Type, 2018–2028
11.4.1. Ductal Carcinoma In Situ (DCIS)
11.4.2. Invasive Breast Cancer
11.4.2.1. Invasive Ductal Carcinoma
11.4.2.2. Invasive Lobular Carcinoma
11.4.2.3. Metastatic Breast Cancer
11.4.2.4. Others
11.5. Market Value Forecast, by End-user, 2018–2028
11.5.1. Hospitals & Ambulatory Surgery Centers
11.5.2. Diagnostic Laboratories
11.5.3. Research & Academic Institutes
11.6. Market Value Forecast, by Country/Sub-region, 2018–2028
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Technique
11.7.2. By Cancer Type
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Global Breast Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Technique, 2018–2028
12.3.1. Imaging
12.3.1.1. Mammography
12.3.1.1.1. Analog Mammography
12.3.1.1.2. Digital Mammography
12.3.1.2. PET/CT Scan
12.3.2. Tissue Biopsy Tests
12.3.3. Molecular Testing
12.4. Market Value Forecast, by Cancer Type, 2018–2028
12.4.1. Ductal Carcinoma In Situ (DCIS)
12.4.2. Invasive Breast Cancer
12.4.2.1. Invasive Ductal Carcinoma
12.4.2.2. Invasive Lobular Carcinoma
12.4.2.3. Metastatic Breast Cancer
12.4.2.4. Others
12.5. Market Value Forecast, by End-user, 2018–2028
12.5.1. Hospitals & Ambulatory Surgery Centers
12.5.2. Diagnostic Laboratories
12.5.3. Research & Academic Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2018–2028
12.6.1. China
12.6.2. India
12.6.3. Japan
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Technique
12.7.2. By Cancer Type
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Global Breast Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Technique, 2018–2028
13.3.1. Imaging
13.3.1.1. Mammography
13.3.1.1.1. Analog Mammography
13.3.1.1.2. Digital Mammography
13.3.1.2. PET/CT Scan
13.3.2. Tissue Biopsy Tests
13.3.3. Molecular Testing
13.4. Market Value Forecast, by Cancer Type, 2018–2028
13.4.1. Ductal Carcinoma In Situ (DCIS)
13.4.2. Invasive Breast Cancer
13.4.2.1. Invasive Ductal Carcinoma
13.4.2.2. Invasive Lobular Carcinoma
13.4.2.3. Metastatic Breast Cancer
13.4.2.4. Others
13.5. Market Value Forecast, by End-user, 2018–2028
13.5.1. Hospitals & Ambulatory Surgery Centers
13.5.2. Diagnostic Laboratories
13.5.3. Research & Academic Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2018–2028
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Technique
13.7.2. By Cancer Type
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East and Africa Global Breast Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Technique, 2018–2028
14.3.1. Imaging
14.3.1.1. Mammography
14.3.1.1.1. Analog Mammography
14.3.1.1.2. Digital Mammography
14.3.1.2. PET/CT Scan
14.3.2. Tissue Biopsy Tests
14.3.3. Molecular Testing
14.4. Market Value Forecast, by Cancer Type, 2018–2028
14.4.1. Ductal Carcinoma In Situ (DCIS)
14.4.2. Invasive Breast Cancer
14.4.2.1. Invasive Ductal Carcinoma
14.4.2.2. Invasive Lobular Carcinoma
14.4.2.3. Metastatic Breast Cancer
14.4.2.4. Others
14.5. Market Value Forecast, by End-user, 2018–2028
14.5.1. Hospitals & Ambulatory Surgery Centers
14.5.2. Diagnostic Laboratories
14.5.3. Research & Academic Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2018–2028
14.6.1. GCC
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Technique
14.7.2. By Cancer Type
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company, 2018
15.3. Company Profiles
15.3.1. Abbott Laboratories
15.3.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.1.2. Product Portfolio
15.3.1.1.3. SWOT Analysis
15.3.1.1.4. Strategic Overview
15.3.2. GE Healthcare (General Electric Company)
15.3.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.1.2. Product Portfolio
15.3.2.1.3. SWOT Analysis
15.3.2.1.4. Strategic Overview
15.3.3. Koninklijke Philips N.V.
15.3.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.1.2. Product Portfolio
15.3.3.1.3. SWOT Analysis
15.3.3.1.4. Strategic Overview
15.3.4. Hologic, Inc.
15.3.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.1.2. Product Portfolio
15.3.4.1.3. SWOT Analysis
15.3.4.1.4. Strategic Overview
15.3.5. C. R. Bard, Inc. (Becton, Dickinson and Company)
15.3.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.1.2. Product Portfolio
15.3.5.1.3. SWOT Analysis
15.3.5.1.4. Strategic Overview
15.3.6. Siemens Healthineers (Siemens AG)
15.3.6.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.1.2. Product Portfolio
15.3.6.1.3. SWOT Analysis
15.3.6.1.4. Strategic Overview
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.1.2. Product Portfolio
15.3.7.1.3. SWOT Analysis
15.3.7.1.4. Strategic Overview
15.3.8. Fujifilm Holding Corporation
15.3.8.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.1.2. Product Portfolio
15.3.8.1.3. SWOT Analysis
15.3.8.1.4. Strategic Overview
15.3.9. Leica Biosystems Nussloch GmbH (Danaher)
15.3.9.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.1.2. Product Portfolio
15.3.9.1.3. SWOT Analysis
15.3.9.1.4. Strategic Overview
15.3.10. bioTheranostics, Inc.
15.3.10.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.1.2. Product Portfolio
15.3.10.1.3. SWOT Analysis
15.3.10.1.4. Strategic Overview
15.3.11. Myriad Genetics, Inc.
15.3.11.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.1.2. Product Portfolio
15.3.11.1.3. SWOT Analysis
15.3.11.1.4. Strategic Overview
List of TablesTable 01: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027
Table 02: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027
Table 03: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027
Table 04: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027
Table 05: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027
Table 06: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 07: Global Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 08: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 09: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027
Table 10: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027
Table 11: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027
Table 12: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027
Table 13: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027
Table 14: North America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 15: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 16: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027
Table 17: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027
Table 18: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027
Table 19: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027
Table 20: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027
Table 21: Europe Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 22: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 23: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027
Table 24: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027
Table 25: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027
Table 26: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027
Table 27: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027
Table 28: Asia Pacific Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 29: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 30: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027
Table 31: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027
Table 32: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027
Table 33: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027
Table 34: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027
Table 35: Latin America Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 36: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 37: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Technique, 2017–2027
Table 38: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Imaging, 2017–2027
Table 39: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Mammography, 2017–2027
Table 40: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2027
Table 41: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by Invasive Breast Cancer, 2017–2027
Table 42: Middle East & Africa Breast Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027